Abstract：
OBJECTIVE: Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a common disease, which was previously approached with sinus surgery or systemic corticosteroids. The advent of biological therapies radically changed the approach to this disease. On the other hand, there is scarce scientific evidence of how specific subsets of patients respond to this treatment.
METHODS: this is a monocentric, prospective study investigating the long-term efficacy on biweekly 300 mg dupilumab therapy in CRSwNP, prescribed to 61 patients. Patients were evaluated at baseline and every 2 months for the first 6 months, then at 9, 12, 16, 20 and 24 months.
RESULTS: dupilumab proved to be an effective treatment, neatly improving both subjective and objective measurements in CRSwNP. The main finding of the study is the difference between specific subgroups of patients: while the overall response is similar, patients with Th2 comorbidities such as asthma and atopy tend to reach a stable response later, with the improvement ongoing even after 6 months of therapy, while non-asthmatic, non-atopic patients attain an earlier stability in response.
CONCLUSIONS: dupilumab provides an excellent long-term control of CRSwNP, but the response in asthmatic and atopic patients appears to be different and delayed when compared to non asthmatic and non atopic ones.
METHODS: this is a monocentric, prospective study investigating the long-term efficacy on biweekly 300 mg dupilumab therapy in CRSwNP, prescribed to 61 patients. Patients were evaluated at baseline and every 2 months for the first 6 months, then at 9, 12, 16, 20 and 24 months.
RESULTS: dupilumab proved to be an effective treatment, neatly improving both subjective and objective measurements in CRSwNP. The main finding of the study is the difference between specific subgroups of patients: while the overall response is similar, patients with Th2 comorbidities such as asthma and atopy tend to reach a stable response later, with the improvement ongoing even after 6 months of therapy, while non-asthmatic, non-atopic patients attain an earlier stability in response.
CONCLUSIONS: dupilumab provides an excellent long-term control of CRSwNP, but the response in asthmatic and atopic patients appears to be different and delayed when compared to non asthmatic and non atopic ones.
摘要：
目的：慢性鼻-鼻窦炎伴鼻息肉（CRSwNP）是一种常见病，以前曾接受鼻窦手术或全身性皮质类固醇治疗。生物疗法的出现从根本上改变了这种疾病的方法。另一方面,缺乏科学证据证明特定的患者亚群对这种治疗有何反应。
方法：这是一个单中心，前瞻性研究调查每两周一次300mgdupilumab治疗在CRSwNP中的长期疗效，给61名患者开处方。在基线和前6个月每2个月对患者进行评估，然后在9、12、16、20和24个月。
结果：dupilumab被证明是一种有效的治疗方法，巧妙地改善了CRSwNP中的主观和客观测量。该研究的主要发现是特定亚组患者之间的差异：虽然总体反应相似，Th2合并症患者，如哮喘和特应性，往往在以后达到稳定的反应，即使在治疗6个月后仍在改善，虽然没有哮喘，非特应性患者在反应中获得较早的稳定性。
结论：dupilumab对CRSwNP提供了极好的长期控制，但是与非哮喘和非特应性患者相比，哮喘和特应性患者的反应似乎不同且延迟。
方法：这是一个单中心，前瞻性研究调查每两周一次300mgdupilumab治疗在CRSwNP中的长期疗效，给61名患者开处方。在基线和前6个月每2个月对患者进行评估，然后在9、12、16、20和24个月。
结果：dupilumab被证明是一种有效的治疗方法，巧妙地改善了CRSwNP中的主观和客观测量。该研究的主要发现是特定亚组患者之间的差异：虽然总体反应相似，Th2合并症患者，如哮喘和特应性，往往在以后达到稳定的反应，即使在治疗6个月后仍在改善，虽然没有哮喘，非特应性患者在反应中获得较早的稳定性。
结论：dupilumab对CRSwNP提供了极好的长期控制，但是与非哮喘和非特应性患者相比，哮喘和特应性患者的反应似乎不同且延迟。
